Rubius Therapeutics, Inc.

Rubius Therapeutics, Inc.

Rubius Therapeutics, Inc.

Overview
Headquarters

399 Binney Street, Suite 300, Cambridge, MA, 02139, USA

Type of Company

Public

Employees (Worldwide)

142

Industries

Biotechnology
Pharmaceuticals
Hospitals & Patient Services

Company Description

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Rubius Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Scientific Officer

Chief Legal Officer & Corporate Secretary

Chief Medical Officer

Chief Quality Officer & Senior Vice President

Chief People Officer & Senior Vice President

Chief of Staff

Senior Vice President, Business Development & Strategy

Senior Vice President, Finance & Operations

Board of Directors

Executive Partner at Flagship Pioneering

Co-Founder at Moderna, Inc.

Co-Founder at Radius Health, Inc.

Lead Corporate Development at Bioaxone Therapeutics, Inc.

Head-Corporate Finance & Strategy at Mesoblast Ltd.

Former Chief Scientific Officer & Executive Vice President at Bristol-Myers Squibb Company

Chief Executive Officer at Rubius Therapeutics, Inc.

President, Chief Executive Officer & Director at Audentes Therapeutics, Inc.

Former Chief Executive Officer at Syncona Ltd.

Paths to Rubius Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Rubius Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Recent Transactions
Details Hidden

Rubius Therapeutics, Inc. issued USD Common Stock

Details Hidden

Rubius Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Rubius Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Associate

Advised onRubius Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

Co-Founder at Pulmatrix, Inc. (Inactive)

Senior Advisor

Senior Partner at Flagship Pioneering

Scientific Advisor

Former Chief Medical Officer at Rubius Therapeutics, Inc.

Key Stats and Financials As of 2018
Market Capitalization
$712M
Total Enterprise Value
$297M
Earnings Per Share
$-2.27
Revenue
$0
EBITDA
$-90.4M
Net Profit
$-89.2M
Total Debt
$70.3M
Total Equity
$393M
TEVNet Income
-3.33x
Debt TEV
0.24x
Investors
Details Hidden

Flagship Pioneering focuses on investments in the following sectors: (1) therapeutics (2) life science tools and diagnostics and (3) bioenergy and clean technology. The firm looks for companies with exceptional management teams and significant commercial opportunities resulting from market discontinuities or technology breakthroughs. Flagship Ventures typically serves as lead investor. The majority of their investments are seed or first round investments. Initial investments range from $250,000 to $5 million, with typically initial investments ranging from $2.5 million to $4 million. Flagship Ventures may invest up to $15 million to $20 million over the life of a venture and typically forms syndicates that include other venture capital firms

Suppliers
Whitehead Institute for Biomedical Research Biotechnology | Cambridge, MA

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers. Located in Cambridge, Massachusetts, Whitehead Institute was founded in 1982 by businessman and philanthropist Edwin C. “Jack” Whitehead.

BioLife Solutions Inc. Industrial Machinery & Manufacturing | Bothell, Washington

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Synlogic, Inc. Biotechnology - Cambridge, MA

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Rubius Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Rubius Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Rubius Therapeutics, Inc..